Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project-Reference-Cited by-同舟云学术

Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project

Published:2024-08-02 Issue:5 Volume:13 Page:1415-1430
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Paolicelli Damiano,Borriello Giovanna,Clerici Raffaella,Colombo Elena,Croce Davide,D’Amico Emanuele,De Rossi Nicola,Di Sapio Alessia,Fenu Giuseppe,Maimone Davide,Marfia Girolama A.,Moccia Marcello,Perini Paola,Piscaglia Maria G.,Razzolini Lorenzo,Riccaboni Massimo,Signoriello Elisabetta,Agostoni Gianluca,Farina Alberto,Mondino Margaret,Berruto Francesco,Tettamanti Alessia,Donnaloja Francesca^ORCID,Tortorella Carla

Funder

Sanofi Italia

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40120-024-00644-3.pdf

Reference33 articles.

1. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022–4.

2. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622–36.

3. Niglio T, Mandolesi S, De Lucia O, d’Alessandro A. The incidence of the multiple sclerosis in Italy: 2011–2015. Clin Ter. 2022;173(5):453–7.

4. Puthenparampil M, Perini P, Bergamaschi R, Capobianco M, Filippi M, Gallo P. Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors. J Neurol. 2022;269(4):1817–24.

5. Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F, et al. Multiple sclerosis. Lancet. 2024;403(10422):183–202.